Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab: Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain… #immunology https://t.co/WJoPS
Targeted escape of SARSCoV-l2 in vitro from mAb S309, precursor of sotrovimab. evolving AA exchanges R346S and P337L located in paratope of S309;antibody lost affinity to RBD carrying P337L or both amino acid exchanges, while ACE2 binding was not affected
New Research: Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab: Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain… https://t.co/CeW